The effects of tirofiban on peripheral markers of oxidative stress and endothelial dysfunction in patients with acute coronary syndromes

Thrombosis Research

Volumn 119, Issue 2, 2007, Pages 167-174

  Iliodromitis, Efstathios K ^a   Andreadou, Ioanna ^c   Markantonis Kyroudis, Sophia ^c   Mademli, Kalliopi ^c   Kyrzopoulos, Stamatis ^b   Georgiadou, Panagiota ^b   Kremastinos, Dimitrios Th ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ONASSIS CARDIAC SURGERY CENTER   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

Acute coronary syndromes; Endothelium; Oxidative stress; Tirofiban

Indexed keywords

BIOLOGICAL MARKER; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MALONALDEHYDE; PLACEBO; TIROFIBAN; TROPONIN I; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CORONARY SYNDROME; ADULT; ANGINA PECTORIS; ARTICLE; CELL INTERACTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ECG ABNORMALITY; ENDOTHELIAL DYSFUNCTION; FEMALE; HOSPITALIZATION; HUMAN; MALE; NEUTROPHIL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; BIOLOGICAL MARKERS; CORONARY DISEASE; ENDOTHELIUM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPHILS; OXIDATIVE STRESS; TIME FACTORS; TYROSINE;

EID: 33751341794     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.02.002     Document Type: Article

References (31)

1. Channon K. Oxidative stress and coronary plaque stability. Arterioscler Thromb Vasc Biol 22 (2002) 1751-1752
2. Heitzer T., Schlinzig T., Krohn K., Meinertz T., and Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104 (2001) 2673-2678
3. Lefkovits J., Plow E.F., and Topol E.J. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 332 23 (1995) 15553-15559
4. Mousa S.A. Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonists and beyond. Drug Discov Today 4 12 (1999) 552-561
5. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 96 (1997) 1445-1453
6. The CAPTURE Investigators. Randomized Placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 349 (1997) 1623-1629
7. The PURSUIT investigators. Inhibition of platelet glycoprotein IIb/IIIa receptor with eptifibatide in patients with acute coronary syndromes. N Engl J Med 339 (1998) 436-443
8. The PRISM investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 338 (1998) 1498-1505
9. The PRISM-PLUS investigators. Inhibition of platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non Q wave myocardial infarction. N Engl J Med 338 (1998) 1488-1497
10. The PARAGON investigators. International, randomized, controlled trial of lamifiban, heparin or both in unstable angina. Circulation 97 (1998) 2386-2395
11. Seligmann C., Schimmer M., Leitsch T., Bock A., Simsek Y., Tschope C., et al. A thrombocyte-induced myocardial dysfunction in the ischemic and reperfused guinea pig heart is mediated by reactive oxygen species. Free Radic Biol Med 29 12 (2000) 1244-1251
12. Gorog P., and Kovacs I. Lipid peroxidation by activated platelets: a possible link between thrombosis and atherogenesis. Atherosclerosis 115 (1995) 121-128
13. Forde R., and Fitzgerald D. Reactive oxygen species and platelet activation in reperfusion injury. Circulation 95 4 (1997) 787-789
14. Braunwald E. Unstable angina: a classification. Circulation 80 (1989) 410-413
15. Blazing M.A., de Lemos J.A., White H.D., Fox K.A., Verheugt F.W., Ardissino D., et al. Safety and efficacy of enoxaparin vs. unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 292 (2004) 55-64
16. Andreadou I., Iliodromitis E.K., Mikros E., Bofilis E., Zoga A., Constantinou M., et al. Melatonin does not prevent the protection of ischemic preconditioning in vivo despite its antioxidant effect against oxidative stress. Free Radic Biol Med 37 4 (2004) 500-510
17. Iqbal K., Rauoof M., Mir M., Tramboo N.A., Malik J.A., Naikoo B.A., et al. Lipid peroxidation during acute coronary syndromes and its intensification at the time of myocardial ischemia reperfusion. Am J Cardiol 89 (2002) 334-337
18. Chamiec T., Herbaczynska-Cedro K., and Ceremuzynski L. Effects of antioxidant vitamins C and E on signal-averaged electrocardiogram in acute myocardial infarction. Am J Cardiol 77 4 (1996) 237-241
19. Pucheu S., Coudray C., Vanzetto G., Favier A., Machecourt J., and de Leiris J. Assessment of radical activity during the acute phase of myocardial infarction following fibrinolysis: utility of assaying plasma malondialdehyde. Free Radic Biol Med 19 6 (1995) 873-881
20. De Scheerder I.K., van de Kraay A.M., Lamers J.M., Koster J.F., de Jong J.W., and Serruys P.W. Myocardial malondialdehyde and uric acid release after short-lasting coronary occlusions during coronary angioplasty: potential mechanisms for free radical generation. Am J Cardiol 68 4 (1991) 392-395
21. Jayakumari N., Ambikakumari V., Balakrishnan K.G., and Iyer K.S. Antioxidant status in relation to free radical production during stable and unstable anginal syndromes. Atherosclerosis 94 2-3 (1992) 183-190
22. Holvoet P., Vanhaecke J., Janssens S., Van de Werf F., and Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98 (1998) 1487-1494
23. Aviram M., Dankner G., and Brook J.G. Platelet secretory-products increase low density lipoprotein oxidation, enhance its uptake by macrophages, and reduce its fluidity. Arteriosclerosis 10 (1990) 559-563
24. Aviram M., Fuhrman B., Keidar S., Maor I., Rosenblat M., Dankner G., et al. Platelet-modified low-density lipoprotein induces macrophage cholesterol accumulation and platelet activation. J Clin Chem Clin Biochem 27 (1989) 3-12
25. Seligmann C., Simsek Y., Schimmer M., Leitsch T., Bock A., and Schultheiss H.P. Human thrombocytes are able to induce a myocardial dysfunction in the ischemic and reperfused guinea pig heart mediated by free radicals-role of the GPIIb/IIIa-blocker tirofiban. Life Sci 71 19 (2002) 2319-2329
26. Aukrust P., Weahre T., Damas J.K., Gullestad L., and Solum N.O. Inflammatory role of platelets in acute coronary syndromes. Heart 86 (2001) 605-606
27. Freedman J.E., and Loscalzo J. Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation 105 (2002) 2130-2132
28. Lindemann S., Tolley N.D., Dixon D.A., McIntyre T.M., Prescott S.M., Zimmerman G.A., et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1_synthesis. J Cell Biol 154 (2001) 485-490
29. May A.E., Kälsch T., Massberg S., Herouy Y., Schmidt R., and Gawaz M. Engagement of glycoprotein IIb/IIIa (_IIb_3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 106 (2002) 2111-2117
30. Azar R., Badaoui G., Sarkis A., Kassab R., Salame E., Klayme S., et al. Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease. Am J Cardiol 95 (2005) 236-240
31. Ercan E., Bozdemir H., Tengiz I., Sekuri C., Aliyev E., Akilli A., et al. Decreased soluble cell adhesion molecules after tirofiban infusion in patients with unstable angina pectoris. Thromb J 2 1 (2004) 4